More battles in store The Hindu In March 2012, soon after the decision of the Indian Patent Controller to grant a compulsory licence for Sorafenib (used in the treatment of liver and kidney cancers), Roche announced a cut in the Herceptin price, from Rs.1.08 lakh a dose to Rs. 92,000 ... |
